Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO management and treatment adapted recommendations in the COVID-19 era: Diffuse large B-cell lymphoma, Mantle cell lymphoma and Aggressive T-cell lymphomas

The tiered approach of ESMO in delivering a guidance for cancer patients during the COVID-19 pandemic is designed across three levels of priorities, namely: tier 1 (high priority intervention), 2 (medium priority) and 3 (low priority) – defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS), incorporating the information on the value-based prioritisation and clinical cogency of the interventions

  • High priority: Patient's condition is immediately life threatening, clinically unstable, and/or the magnitude of benefit qualifies the intervention as high priority (e.g. significant overall survival [OS] gain and/or substantial improvement in quality of life [QoL]);
  • Medium priority: Patient's situation is non-critical but delay beyond 6 weeks could potentially impact overall outcome and/or the magnitude of benefit qualifies for intermediate priority;
  • Low priority: Patient's condition is stable enough that services can be delayed for the duration of the COVID-19 pandemic and/or the intervention is non-priority based on the magnitude of benefit (e.g. no survival gain with no change nor reduced QoL).

Priorities for diffuse large B-cell lymphoma (DLBCL) patients 

High Priority

  • Curative treatment for aggressive lymphomas:
    • Chemotherapy schedules may be modified so as to reduce clinical visits without compromising the curative potential of the treatment
    • Patients should receive G-CSF growth factor support so as to minimise neutropaenia
    • Less myelosuppressive regimens may be preferred (e.g. CHOP-21 instead of CHOEP-14 or ACVBP)
  • High-dose chemotherapy with autologous stem cell support in relapse of DLBCL
  • Continuation of treatment in the context of a clinical trial
  • CAR T-cell therapy in refractory DLBCL

Medium Priority

  • Non-curative treatment (e.g. systemic therapy for relapsed aggressive lymphoma, not eligible for autologous stem cell transplant) may be modified so as to reduce clinical visits
    • Patients should receive G-CSF growth factor support so as to minimise neutropaenia
    • Avoid T-cell suppressive agents (bendamustine)
  • CNS prophylaxis with high-dose methotrexate, high-dose cytarabine and/or intrathecal methotrexate may be omitted
  • Palliative radiotherapy may be delayed
  • Consolidation radiotherapy (e.g. due to initial bulk or extranodal disease) may be delayed

 Low Priority

-

Priorities for for Mantle cell lymphoma (MCL) patients

High Priority

  • First-line treatment for MCL:
    • Chemotherapy schedules may be modified so as to reduce clinical visits
    • Patients should receive G-CSF growth factor support so as to minimise neutropaenia
  • Continuation of treatment in the context of a clinical trial

Medium Priority

  • Systemic therapy for relapsed MCL may be modified so as to reduce clinical visits
    • Patients should receive G-CSF growth factor support so as to minimise neutropaenia
    • Avoid T-cell suppressive agents (bendamustine)
  • High-dose chemotherapy with autologous stem cell support as consolidation therapy may be delayed
  • Maintenance therapy with rituximab may be delayed
  • Palliative radiotherapy may be delayed

 Low Priority

-

Priorities for Aggressive T-cell lymphoma patients

High Priority

  • First-line treatment:
    • Chemotherapy schedules may be modified so as to reduce clinical visits
    • Patients should receive G-CSF growth factor support so as to minimise neutropaenia
  • Continuation of treatment in the context of a clinical trial

Medium Priority

  • Systemic therapy for relapsed disease may be modified so as to reduce clinical visits
    • Patients should receive G-CSF growth factor support so as to minimise neutropaenia
    • Avoid T-cell suppressive agents (bendamustine)
  • High-dose chemotherapy with autologous stem cell support as consolidation therapy may be delayed
  • Palliative radiotherapy may be delayed

 Low Priority

-

 

List of abbreviations: ACVBP, doxorubicin/cyclophosphamide/vindesine/bleomycin/prednisone; CAR, chimeric antigen receptor; CHOEP, cyclophosphamide/doxorubicin/vincristine/etoposide/prednisolone; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisolone; COVID-19, severe acute respiratory syndrome coronavirus 2-related disease; CNS, central nervous system; G-CSF, granulocyte colony-stimulating factor.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings